US court says Eisai's Aciphex patent can be enforced
This article was originally published in Scrip
Executive Summary
A US federal appeals court has affirmed the validity and enforceability of Eisai's compound patent for Aciphex (rabeprazole), protecting the blockbuster proton pump inhibitor from generic competition until 2013.